These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 17002258)

  • 1. Cardiovascular effects of insulin sensitizers in diabetes.
    Jawa A; Fonseca V
    Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs and clinical trials in diabetes and hypertension.
    Nilsson P
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():64-9. PubMed ID: 9288549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    Anan F; Masaki T; Fukunaga N; Teshima Y; Iwao T; Kaneda K; Umeno Y; Okada K; Wakasugi K; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2007 Sep; 37(9):709-14. PubMed ID: 17696960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of PPARs in the microvascular dysfunction in diabetes.
    Vinik A; Parson H; Ullal J
    Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cardiovascular benefits of insulin sensitizers.
    Kunhiraman BP; Jawa A; Fonseca VA
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
    MMW Fortschr Med; 2003 Oct; 145(41):47. PubMed ID: 14655486
    [No Abstract]   [Full Text] [Related]  

  • 19. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
    Laakso M
    Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.